Sangamo Therapeutics Inc Financials
This page shows Sangamo Therapeutics Inc (SGMO) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 17 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores
Sangamo Therapeutics Inc has an operating margin of -306.5%, meaning the company retains $-307 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is down from -179.9% the prior year.
Sangamo Therapeutics Inc's revenue declined 31.6% year-over-year, from $57.8M to $39.6M. This contraction results in a growth score of 0/100.
Sangamo Therapeutics Inc's current ratio of 0.84 means current assets barely cover short-term liabilities. This tight liquidity results in a low score of 12/100, which could limit financial flexibility.
While Sangamo Therapeutics Inc generated -$97.2M in operating cash flow, capex of $102K consumed most of it, leaving -$97.3M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.
Sangamo Therapeutics Inc passes 2 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.
For every $1 of reported earnings, Sangamo Therapeutics Inc generates $0.79 in operating cash flow (-$97.2M OCF vs -$122.9M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Earnings & Revenue
Sangamo Therapeutics Inc generated $39.6M in revenue in fiscal year 2025. This represents a decrease of 31.6% from the prior year.
Sangamo Therapeutics Inc's EBITDA was -$117.3M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 18.6% from the prior year.
Sangamo Therapeutics Inc reported -$122.9M in net income in fiscal year 2025. This represents a decrease of 25.5% from the prior year.
Sangamo Therapeutics Inc earned $-0.44 per diluted share (EPS) in fiscal year 2025. This represents an increase of 10.2% from the prior year.
Cash & Balance Sheet
Sangamo Therapeutics Inc generated -$97.3M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 44.4% from the prior year.
Sangamo Therapeutics Inc held $20.9M in cash against $0 in long-term debt as of fiscal year 2025.
Sangamo Therapeutics Inc had 414M shares outstanding in fiscal year 2025. This represents an increase of 94.6% from the prior year.
Margins & Returns
Sangamo Therapeutics Inc's operating margin was -306.5% in fiscal year 2025, reflecting core business profitability. This is down 126.7 percentage points from the prior year.
Sangamo Therapeutics Inc's net profit margin was -310.8% in fiscal year 2025, showing the share of revenue converted to profit. This is down 141.4 percentage points from the prior year.
Capital Allocation
Sangamo Therapeutics Inc invested $112.7M in research and development in fiscal year 2025. This represents an increase of 1.0% from the prior year.
Sangamo Therapeutics Inc invested $102K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 61.8% from the prior year.
SGMO Income Statement
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $581K-96.8% | $18.3M+184.4% | $6.4M-14.8% | $7.6M-84.7% | $49.4M+13779.8% | $356K-26.0% | $481K-76.4% | $2.0M |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $28.1M+3.9% | $27.1M+4.1% | $26.0M+9.8% | $23.7M-14.6% | $27.7M+14.5% | $24.2M-32.5% | $35.9M-29.2% | $50.7M |
| SG&A Expenses | $8.0M-12.0% | $9.1M-9.8% | $10.1M+2.0% | $9.9M-10.7% | $11.0M-8.3% | $12.0M+2.4% | $11.8M-10.2% | $13.1M |
| Operating Income | -$35.6M-99.1% | -$17.9M+39.7% | -$29.6M-14.0% | -$26.0M-344.5% | $10.6M+128.7% | -$37.1M+28.0% | -$51.5M+17.0% | -$62.1M |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | -$161K-696.3% | $27K-77.3% | $119K+127.9% | -$427K-585.2% | $88K+18.9% | $74K-24.5% | $98K+136.0% | -$272K |
| Net Income | -$34.9M-74.8% | -$20.0M+34.7% | -$30.6M-30.8% | -$23.4M-319.2% | $10.7M+129.5% | -$36.1M+26.4% | -$49.1M+18.6% | -$60.3M |
| EPS (Diluted) | $-0.11-37.5% | $-0.08+42.9% | $-0.14 | N/A | $0.04+122.2% | $-0.18+33.3% | $-0.27 | N/A |
SGMO Balance Sheet
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $88.6M-9.1% | $97.6M+13.2% | $86.2M-15.2% | $101.6M-8.7% | $111.3M+19.6% | $93.0M-27.9% | $129.0M-22.0% | $165.3M |
| Current Assets | $44.1M-11.7% | $49.9M+32.7% | $37.6M-27.3% | $51.7M-11.1% | $58.1M+45.1% | $40.1M-41.6% | $68.6M-27.2% | $94.3M |
| Cash & Equivalents | $29.6M-22.8% | $38.3M+52.3% | $25.2M-39.9% | $41.9M+6.9% | $39.2M+41.1% | $27.8M-48.9% | $54.4M+20.4% | $45.2M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | $523K+40.6% | $372K+1.6% | $366K-30.4% | $526K-95.0% | $10.5M+1706.5% | $581K-15.9% | $691K-25.1% | $923K |
| Goodwill | N/A | N/A | N/A | $0 | N/A | N/A | N/A | $0 |
| Total Liabilities | $82.4M+5.7% | $78.0M-4.1% | $81.3M+3.0% | $78.9M+9.3% | $72.1M+4.0% | $69.3M-4.1% | $72.3M-12.3% | $82.4M |
| Current Liabilities | $50.1M+5.2% | $47.7M-3.8% | $49.6M+8.2% | $45.8M+6.1% | $43.2M+10.7% | $39.0M-3.1% | $40.2M-15.7% | $47.7M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $6.2M-68.2% | $19.6M+299.6% | $4.9M-78.5% | $22.8M-41.8% | $39.1M+65.2% | $23.7M-58.2% | $56.7M-31.6% | $82.9M |
| Retained Earnings | -$1.6B-2.2% | -$1.6B-1.3% | -$1.5B-2.0% | -$1.5B-1.6% | -$1.5B+0.7% | -$1.5B-2.5% | -$1.5B-3.5% | -$1.4B |
SGMO Cash Flow Statement
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$28.5M-56.9% | -$18.2M+30.6% | -$26.1M-680.3% | -$3.4M-128.5% | $11.8M+143.7% | -$26.9M+44.8% | -$48.7M+3.7% | -$50.5M |
| Capital Expenditures | $64K | N/A | N/A | $152K+32.2% | $115K | $0 | $0-100.0% | $2.7M |
| Free Cash Flow | -$28.6M | N/A | N/A | -$3.5M-130.1% | $11.6M+143.3% | -$26.9M+44.8% | -$48.7M+8.5% | -$53.2M |
| Investing Cash Flow | -$64K-166.7% | -$24K | $0-100.0% | $1.3M+468.2% | $233K+83.5% | $127K-99.6% | $35.8M-5.0% | $37.7M |
| Financing Cash Flow | $19.2M-32.9% | $28.6M+251.8% | $8.1M+16.3% | $7.0M+3543.8% | -$203K+61.9% | -$533K-102.4% | $22.1M+13146.7% | $167K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
SGMO Financial Ratios
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | -6119.3%-6021.7pp | -97.5%+362.7pp | -460.3%-116.1pp | -344.2%-365.7pp | 21.5%+10438.4pp | -10416.8%+295.4pp | -10712.3%-7673.1pp | -3039.1% |
| Net Margin | -6012.1%-5902.9pp | -109.2%+366.2pp | -475.3%-165.5pp | -309.8%-331.4pp | 21.6%+10169.9pp | -10148.3%+57.3pp | -10205.6%-7252.9pp | -2952.7% |
| Return on Equity | -559.5%-457.6pp | -102.0%+521.7pp | -623.7%-520.9pp | -102.8%-130.0pp | 27.3%+179.8pp | -152.5%-65.9pp | -86.6%-13.8pp | -72.7% |
| Return on Assets | -39.4%-18.9pp | -20.5%+15.0pp | -35.5%-12.5pp | -23.0%-32.6pp | 9.6%+48.4pp | -38.8%-0.8pp | -38.1%-1.6pp | -36.5% |
| Current Ratio | 0.88-0.2 | 1.05+0.3 | 0.76-0.4 | 1.13-0.2 | 1.35+0.3 | 1.03-0.7 | 1.71-0.3 | 1.98 |
| Debt-to-Equity | 13.20+9.2 | 3.98-12.6 | 16.56+13.1 | 3.46+1.6 | 1.84-1.1 | 2.93+1.7 | 1.27+0.3 | 0.99 |
| FCF Margin | -4916.0% | N/A | N/A | -46.4%-70.0pp | 23.6%+7575.3pp | -7551.7%+2565.4pp | -10117.1%-7511.3pp | -2605.7% |
Note: Shareholder equity is negative (-$14.3M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.84), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Frequently Asked Questions
What is Sangamo Therapeutics Inc's annual revenue?
Sangamo Therapeutics Inc (SGMO) reported $39.6M in total revenue for fiscal year 2025. This represents a -31.6% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Sangamo Therapeutics Inc's revenue growing?
Sangamo Therapeutics Inc (SGMO) revenue declined by 31.6% year-over-year, from $57.8M to $39.6M in fiscal year 2025.
Is Sangamo Therapeutics Inc profitable?
No, Sangamo Therapeutics Inc (SGMO) reported a net income of -$122.9M in fiscal year 2025, with a net profit margin of -310.8%.
What is Sangamo Therapeutics Inc's EBITDA?
Sangamo Therapeutics Inc (SGMO) had EBITDA of -$117.3M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Sangamo Therapeutics Inc's operating margin?
Sangamo Therapeutics Inc (SGMO) had an operating margin of -306.5% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Sangamo Therapeutics Inc's net profit margin?
Sangamo Therapeutics Inc (SGMO) had a net profit margin of -310.8% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Sangamo Therapeutics Inc's free cash flow?
Sangamo Therapeutics Inc (SGMO) generated -$97.3M in free cash flow during fiscal year 2025. This represents a -44.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Sangamo Therapeutics Inc's operating cash flow?
Sangamo Therapeutics Inc (SGMO) generated -$97.2M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Sangamo Therapeutics Inc's total assets?
Sangamo Therapeutics Inc (SGMO) had $59.7M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Sangamo Therapeutics Inc's capital expenditures?
Sangamo Therapeutics Inc (SGMO) invested $102K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Sangamo Therapeutics Inc spend on research and development?
Sangamo Therapeutics Inc (SGMO) invested $112.7M in research and development during fiscal year 2025.
What is Sangamo Therapeutics Inc's current ratio?
Sangamo Therapeutics Inc (SGMO) had a current ratio of 0.84 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
What is Sangamo Therapeutics Inc's debt-to-equity ratio?
Sangamo Therapeutics Inc (SGMO) had a debt-to-equity ratio of -5.19 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Sangamo Therapeutics Inc's return on assets (ROA)?
Sangamo Therapeutics Inc (SGMO) had a return on assets of -205.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Sangamo Therapeutics Inc's cash runway?
Based on fiscal year 2025 data, Sangamo Therapeutics Inc (SGMO) had $20.9M in cash against an annual operating cash burn of $97.2M. This gives an estimated cash runway of approximately 3 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
Why is Sangamo Therapeutics Inc's debt-to-equity ratio negative or unusual?
Sangamo Therapeutics Inc (SGMO) has negative shareholder equity of -$14.3M as of fiscal year 2025, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is Sangamo Therapeutics Inc's Piotroski F-Score?
Sangamo Therapeutics Inc (SGMO) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Sangamo Therapeutics Inc's earnings high quality?
Sangamo Therapeutics Inc (SGMO) has an earnings quality ratio of 0.79x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Sangamo Therapeutics Inc?
Sangamo Therapeutics Inc (SGMO) scores 3 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.